NCT01566604 - Efficacy, Safety and Tolerability of NVA237 in Patients With Chronic Obstructive Pulmonary Disease | Biotech Hunter

Enrollment

460

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG

NVA237

Delivered via a single dose dry powder inhaler

DRUG

Placebo

Delivered via a single dose dry powder inhaler

Trial Locations (32)

1000

Novartis Investigative Site, Manila

1100

Novartis Investigative Site, Quezon City

1740

Novartis Investigative Site, Las Piñas

3020

Novartis Investigative Site, Bulacan

100023

Novartis Investigative Site, Beijing

100029

Novartis Investigative Site, Beijing

100730

Novartis Investigative Site, Beijing

110016

Novartis Investigative Site, Shengyang

110063

Novartis Investigative Site, Dehli

200025

Novartis Investigative Site, Shanghai

200032

Novartis Investigative Site, Shanghai

200433

Novartis Investigative Site, Shanghai

215004

Novartis Investigative Site, Suzhou

300052

Novartis Investigative Site, Tianjin

330006

Novartis Investigative Site, Nanchang

400037

Novartis Investigative Site, Chongqing

400038

Novartis Investigative Site, Chongqing

400042

Novartis Investigative Site, Chongqing

410011

Novartis Investigative Site, Changsha

510080

Novartis Investigative Site, Guangzhou

530021

Novartis Investigative Site, Nanning

610041

Novartis Investigative Site, Chengdu

710032

Novartis Investigative Site, Xi’an

050000

Novartis Investigative Site, Shijiazhuang

Unknown

Novartis Investigative Site, Nanjing

641 045.

Novartis Investigative Site, Coimbatore

130-709

Novartis Investigative Site, Seoul

150-713

Novartis Investigative Site, Seoul

301-804

Novartis Investigative Site, Daejeon

403-010

Novartis Investigative Site, Incheon

137-701

Novartis Investigative Site, Seoul